Please use this identifier to cite or link to this item:
Title: Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
Author: Bachert, Claus
Hellings, Peter W.
Mullol i Miret, Joaquim
Naclerio, Robert M.
Chao, Jingdong
Amin, Nikhil
Grabher, Annette
Swanson, Brian N.
Hamilton, Jennifer D.
Guillonneau, Sophie
Christine Taniou
Zhang, Donghui
Pirozzi, Gianluca
Graham, Neil M. H.
Staudinger, Heribert
Mannent, Leda P.
Khan, Asif
Keywords: Asma
Issue Date: 27-Mar-2019
Publisher: Elsevier
Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory condition affecting the upper airways, with chronic symptoms such as nasal congestion, partial (hyposmia) or total (anosmia) loss of smell, anterior/posterior rhinorrhea, and mild facial pain.1 As many as 66% of patients with CRSwNP have comorbid asthma and suffer from more severe nasal obstruction, higher levels of lower airway inflammation, and worse asthma control than those without CRS.2, 3 Thus, patients with CRSwNP and comorbid asthma have a high disease burden, seriously impacting health-related quality of life (HRQoL).2, 3 Markers of type 2-mediated inflammation and antibody production (eg, IL-5, IgE) are associated with both CRSwNP and asthma pathogenesis.2
Note: Reproducció del document publicat a:
It is part of: The Journal of Allergy and Clinical Immunology: In Practice, 2019, vol. 7, num. 7, p. 2447-2449.e2
Related resource:
ISSN: 2213-2198
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
12474_4899058_dupilumab_improves.pdf344.86 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons